Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a leading biopharmaceutical company based in China, has announced that it has received market approval in Indonesia for its in-house developed Category 1 drug, the recombinant Mycobacterium tuberculosis fusion protein (EC) injection. This development marks an important milestone for the company as it expands the global reach of its innovative diagnostic tool.
The EC injection is utilized for the diagnosis of Mycobacterium tuberculosis infection and serves as an auxiliary diagnostic for tuberculosis. Since its initial approval for marketing in China in 2020, the drug has gained recognition for its efficacy and reliability. Its inclusion in the National Reimbursement Drug List (NRDL) in China in 2023 further underscores its importance in the country’s healthcare system.
With this latest approval in Indonesia, Chongqing Zhifei Biological Co., Ltd continues to demonstrate its commitment to improving global public health by making its cutting-edge diagnostic solutions available to a broader international audience.- Flcube.com
